bims-madeba Biomed News
on Mal de débarquement syndrome
Issue of 2023–02–19
one paper selected by
Jun Maruta, Mount Sinai Health System



  1. Otol Neurotol. 2023 Feb 15.
       OBJECTIVE: The purpose of this study was to review current treatment options available for mal de debarquement syndrome (MdDS).
    DATA SOURCES: Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Review guidelines, we performed systematic search queries for MdDS-related texts. Documents must have been in the English language, and the time frame was all documents up until May 23, 2022.
    METHODS: Studies were selected if they were published in a peer-reviewed journal and if one of the primary objectives was the assessment of treatment for MdDS. The quality and validity of all documents were assessed by two independent co-investigators. Conflicts were resolved by a third investigator.
    RESULTS: One hundred ninety-four unique references were identified and underwent review. Ninety-seven were selected for full-text review, and 32 studies were ultimately included. Data were stratified by treatment methodology for MdDS. The categories used were pharmacologic, physical therapy, and neuromodulating stimulation.
    CONCLUSIONS: Improvement in patient-reported outcomes is reported with several treatment modalities including specific protocols of vestibular rehabilitation, neuromodulating stimulation, and pharmacologic management with several types of neurotropic drugs.
    DOI:  https://doi.org/10.1097/MAO.0000000000003832